New drug trial aims to ease muscle weakness in myasthenia gravis

NCT ID NCT06282159

Ongoing Disease control Sponsor: Dianthus Therapeutics Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 10, 2026 · Updated 28 times

Summary

This study tests an experimental drug called DNTH103 in 65 adults with generalized myasthenia gravis, a condition causing muscle weakness. Participants receive either the drug or a placebo to see if it safely improves daily activities like talking, swallowing, and breathing. The goal is to control symptoms, not cure the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Clincal Study Site

Tampa, Florida, 33620, United States
Clinical Study Site

Phoenix, Arizona, 85028, United States
Clinical Study Site

Irvine, California, 92868, United States
Clinical Study Site

Stamford, Connecticut, 06905, United States
Clinical Study Site

Boca Raton, Florida, 33487, United States
Clinical Study Site

Bradenton, Florida, 34205, United States
Clinical Study Site

Maitland, Florida, 32751, United States
Clinical Study Site

O'Fallon, Illinois, 62269, United States
Clinical Study Site

Kansas City, Kansas, 66103, United States
Clinical Study Site

Lexington, Kentucky, 40503, United States
Clinical Study Site

Boston, Massachusetts, 02215, United States
Clinical Study Site

East Lansing, Michigan, 48824, United States
Clinical Study Site

Columbia, Missouri, 65212, United States
Clinical Study Site

Cincinnati, Ohio, 45219, United States
Clinical Study Site

Columbus, Ohio, 43221, United States
Clinical Study Site

Dallas, Texas, 75206, United States
Clinical Study Site

Dallas, Texas, 75243, United States
Clinical Study Site

Houston, Texas, 77030, United States
Clinical Study Site

Lubbock, Texas, 79414, United States
Clinical Study Site

Richmond, Virginia, 23219, United States
Clinical Study Site

San Miguel de Tucumán, Tucumán Province, T4000, Argentina
Clinical Study Site

Buenos Aires, 20/11/1902, Argentina
Clinical Study Site

Buenos Aires, C1012AAR, Argentina
Clinical Study Site

Buenos Aires, C1015ABR, Argentina
Clinical Study Site

Córdoba, X5004CDT, Argentina
Clinical Study Site

Rosario, 2000, Argentina
Clinical Study Site

London, Ontario, N6A 5W9, Canada
Clinical Study Site

Ostrava, 70852, Czechia
Clinical Study Site

Copenhagen, 02100, Denmark
Clinical Study Site

Bordeaux, 33076, France
Clinical Study Site

Nice, 06001, France
Clinical Study Site

Strasbourg, 67000, France
Clinical Study Site

Haifa, 3109601, Israel
Clinical Study Site

Ramat Gan, Israel
Clinical Study Site

Safed, 13100, Israel
Clinical Study Site

Milan, 20133, Italy
Clinical Study Site

Naples, 80131, Italy
Clinical Study Site

Pisa, 56126, Italy
Clinical Study Site

Rome, 00168, Italy
Clinical Study Site

Rome, 00189, Italy
Clinical Study Site

Amsterdam, Netherlands
Clinical Study Site

Skopje, 1000, North Macedonia
Clinical Study Site

Bergen, 5021, Norway
Clinical Study Site

Bydgoszcz, 85-065, Poland
Clinical Study Site

Katowice, 40123, Poland
Clinical Study Site

Krakow, 31-202, Poland
Clinical Study Site

Krakow, 31-503, Poland
Clinical Study Site

Lublin, 20-093, Poland
Clinical Study Site

Warsaw, 01-684, Poland
Clinical Study Site

Warsaw, 02-657, Poland
Clinical Study Site

Belgrade, 11000, Serbia
Clinical Study Site

Kragujevac, 34000, Serbia
Clinical Study Site

Niš, 18000, Serbia
Clinical Study Site

Novi Sad, 21000, Serbia
Clinical Study Site

Malmö, Sweden
Clinical Study Site #2

Houston, Texas, 77030, United States

Conditions

Explore the condition pages connected to this study.

MYASTHENIA GRAVIS, GENERALIZED